Stockscreener 앱 받기
8.25
2.36%
0.19
전일 마감가:
$8.06
열려 있는:
$8.11
하루 거래량:
1.13M
Relative Volume:
0.71
시가총액:
$444.10M
수익:
$217.25M
순이익/손실:
$-50.92M
주가수익비율:
-8.25
EPS:
-1
순현금흐름:
$-100.85M
1주 성능:
+7.28%
1개월 성능:
+32.64%
6개월 성능:
-41.78%
1년 성능:
-60.47%
1일 변동 폭
$8.00
$8.335
1주일 범위
$7.3852
$8.335
52주 변동 폭
$4.32
$22.83
Prothena Corporation Plc Stock (PRTA) Company Profile
명칭
Prothena Corporation Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
8.25 | 433.87M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
Recovery Signals Appearing in Prothena Corporation plc Charts2025 Macro Impact & High Conviction Buy Zone Picks - beatles.ru
Prothena Corporation plc Stocks Attracting Dip Buyers2025 Support & Resistance & Accurate Intraday Trade Tips - newsyoung.net
Published on: 2025-08-14 23:29:29 - sundaytimes.kr
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes - Investing.com
Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser
What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser
Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser
Ranking Prothena Corporation plc among high performing stocks via toolsDividend Strategy Summary With 10-Year Outlook - Newser
Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser
How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser
Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India
Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks
Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus
Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan
Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa
Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria
PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus
9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛
Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize
RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener
Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus
JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Prothena Corp PLC Reports Q2 2025 Earnings: EPS Loss of $2.34, Revenue at $4.4 Million, Both Missing Estimates - GuruFocus
Published on: 2025-08-04 19:53:20 - beatles.ru
Prothena Reports Second Quarter 2025 Financial Results and Busin - GuruFocus
How does Prothena Corporation plc generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is the risk reward ratio of investing in Prothena Corporation plc stockMaster stock selection with insider knowledge - Jammu Links News
How strong is Prothena Corporation plc company’s balance sheetInvest smarter with daily stock recommendations - Jammu Links News
What is Prothena Corporation plc company’s growth strategyCapitalize on market shifts with expert advice - Jammu Links News
What catalysts could drive Prothena Corporation plc stock higher in 2025Accelerate your capital gains today - Jammu Links News
Prothena Corporation plc Stock Analysis and ForecastBuild a portfolio that outperforms consistently - Jammu Links News
What are the latest earnings results for Prothena Corporation plcDiscover high-impact stocks for your portfolio - Jammu Links News
Is This a Bottoming Phase for Prothena Corporation plcLow Drawdown Real Time Trading Tips Shared - beatles.ru
Key resistance and support levels for Prothena Corporation plcRisk-Managed Strategy Based on Price Analysis - Newser
Tools to assess Prothena Corporation plc’s risk profileMarket Opportunity Tracker for Swing Traders - Newser
How volatile is Prothena Corporation plc stock compared to the marketEntry Signal Planner To Watch Now - jammulinksnews.com
Intraday pattern recognizer results for Prothena Corporation plcFree Fast Entry High Potential Stock Alerts - Newser
How many analysts rate Prothena Corporation plc as a “Buy”Pre Market Recommendation With Low Risk - Jammu Links News
Can technical indicators confirm Prothena Corporation plc’s reversalCommunity Picked Stocks with Trade Insights - Newser
Prothena Corporation Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):